Cigna Group Files 8-K Report

TL;DR

Cigna Group filed an 8-K, likely routine financial updates.

AI Summary

On March 7, 2024, The Cigna Group filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or new material events were detailed in the provided text snippet.

Why It Matters

This filing indicates routine corporate reporting by The Cigna Group to the SEC, which may contain updates on financial statements or disclosures relevant to investors.

Risk Assessment

Risk Level: low — The filing appears to be a standard 8-K for disclosures and exhibits, not indicating any immediate or significant risks.

Key Players & Entities

• The Cigna Group (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• 001-38769 (identifier) — Commission File Number
• 82-4991898 (identifier) — IRS Employer Identification No.
• 900 Cottage Grove Road (address) — Principal executive offices
• Bloomfield (location) — City of principal executive offices
• Connecticut (location) — State of principal executive offices
• 06002 (zip_code) — Zip code of principal executive offices
• 860-226-600 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, Par Value $0.01 CI New York Stock Exchange , Inc. I
• $235 b — solidated adjusted revenues of at least $235 billion, and adjusted income from operati
• $28.25 — sted income from operations of at least $28.25 per share. This 2024 outlook includes t

Filing Documents

• cigna8k.htm (8-K) — 39KB
• ex99-1.htm (EX-99.1) — 25KB
• image_001.jpg (GRAPHIC) — 7KB
• image_002.jpg (GRAPHIC) — 7KB
• 0000950159-24-000103.txt ( ) — 264KB
• ci-20240307.xsd (EX-101.SCH) — 3KB
• ci-20240307_lab.xml (EX-101.LAB) — 33KB
• ci-20240307_pre.xml (EX-101.PRE) — 22KB
• cigna8k_htm.xml (XML) — 3KB

01

Item 7.01 Regulation FD Disclosure. Outlook and Investor Day Information On March 7, 2024, The Cigna Group (the "Company") issued a press release noting that the Company will host its Investor Day, both in person in New York, New York and virtually, beginning at approximately 8:30 a.m. eastern time. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. During Investor Day, as well as in meetings with investors and analysts over the next several weeks, The Cigna Group officials expect to reaffirm projected full year 2024 consolidated adjusted revenues of at least $235 billion, and adjusted income from operations of at least $28.25 per share. This 2024 outlook includes the impact of expected future share repurchases and anticipated 2024 dividends. The Cigna Group officials also expect to raise long-term average annual adjusted EPS growth target to 10%-14%. The Cigna Group previously discussed its full year 2024 outlook in its press release and investor presentation dated February 2, 2024 and during the related investor conference call. The press release, presentation and the conference call transcript are available on the Investor Relations page of the Company's website located at www.thecignagroup.com. Forward-looking statements in these documents and the related call speak only as of the date they were made. The Investor Day presentations are expected to begin on March 7, 2024 at approximately 8:30 a.m. eastern time and conclude by 12:30 p.m. eastern time. Investors and analysts are invited to listen to the presentation free over the Internet via webcast by visiting the Investor Relations page of the Company's website located at www.thecignagroup.com. The Investor Relations section of the Company's website will also contain materials used during and relating to the Investor Day presentations, including definitions of certain metrics not determined in accordance with accounting principles generally accepted in the United States of

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. The following exhibits are being furnished as part of this report: Exhibit No. Description 99.1 Press release dated March 7, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL).

Forward-Looking Statements

Forward-Looking Statements CAUTIONARY NOTE REGARDING FORWARD-LOOKING This Current Report on Form 8-K (the "Report"), and oral the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on The Cigna Group's current expectations and projections about future trends, events and uncertainties. These statements are not historical facts. Forward-looking statements may include, among others, statements concerning our projected adjusted income from operations outlook for 2024 on a consolidated and per share basis; projected adjusted revenue outlook for 2024; projected adjusted earnings per share outlook on a long-term basis; projected capital deployment, including share repurchases and future dividends, including projected shareholder dividends for 2024; business strategy and strategic or operational initiatives (including our announced solutions or initiatives for certain health care challenges); and other statements regarding The Cigna Group's future beliefs, expectations, plans, intentions, liquidity, cash flows, financial condition or performance. You may identify forward-looking statements by the use of words such as "believe," "expect," "project," "plan," "intend," "anticipate," "estimate," "predict," "potential," "may," "should," "will" or other words or expressions of similar meaning, although not all forward-looking statements contain such terms.

Forward-looking statements are subject to risks and uncertainties,

Forward-looking statements are subject to risks and uncertainties, both known and unknown, that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Such risks and uncertainties include, but are not limited to: our ability to achieve our strategic and operational initiatives; our ability to adapt to changes in an evolving and rapidly changing industry; our ability to compete effectively, differentiate our products and services from those of our competitors and maintain or increase market share; price competition, inflation and other pressures that could compress our margins or result in premiums that are insufficient to cover the cost of services delivered to our customers; the potential for actual claims to exceed our estimates related to expected medical claims; our ability to develop and maintain satisfactory relationships with physicians, hospitals, other health service providers and with producers and consultants; our ability to maintain relationships with one or more key pharmaceutical manufacturers or if payments made or discounts provided decline; changes in the pharmacy provider marketplace or pharmacy networks; changes in drug pricing or industry pricing benchmarks; our ability to invest in and properly maintain our information technology and other business systems; our ability to prevent or contain effects of potential cyberattack or other privacy or data security incidents; risks related to our use of artificial intelligence and machine learning; political, legal, operational, regulatory, economic and other risks that could affect our multinational operations, including currency exchange rates; risks related to strategic transactions and realization of the expected benefits of such transactions, as well as integration or separation difficulties or underperformance relative to expectations; dependence on success of relationships with third parties; risk of significant disruption within our operatio

View Full Filing

View this 8-K filing on SEC EDGAR